References
- National adverse drug reaction monitoring annual report. China: National Medical Products Administration. 2020; https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjyp/20210325170127199.html.
- Guideline for basic intravenous infusion assessment in clinical use. China Pharmaceutical Packaging Association. 2018; https://cnppa.org/index.php/Home/Bz/show_2019/id/941.html.
- United States Pharmacopeia 43 and National Formulary 38. 2020 ed. The United States Pharmacopeial Convention; 2020.
- Huihui L, Xinyi C, Jianghui Q, et al. Determination of insoluble particles in injection and its effect on microcirculation function. China Pharm. 2015;26(10):1369–1372.
- Jianghui Q, Xiulei Z, Qinyue C, et al. Effect of small-sized insoluble particles on inflammation-related indexes in injection. China J Pharm Econ. 2016;11(12):19–21 + 27.
- Shu P, Huifen L, Zhongyuan R, et al. Related factors affecting insoluble particles in infusion. Drug Stand of China. 2019;20(2):101–109.
- Yuejun P, Wenxian Z, Yuan Z. Effect of intravenous particulate pollution on microcirculation of patients with acute respiratory distress syndrome. Shanxi Med J. 2016;45(13):1495–1497.
- Jack T, Boehne M, Brent BE, et al. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med. 2012;38(6):1008–1016. doi: 10.1007/s00134-012-2539-7.
- Sasse M, Dziuba F, Jack T, et al. In-line filtration decreases systemic inflammatory response syndrome, renal and hematologic dysfunction in pediatric cardiac intensive care patients. Pediatr Cardiol. 2015;36(6):1270–1278. doi: 10.1007/s00246-015-1157-x.
- Pharmacopoeia TCo. Pharmacopoeia of People’s Republic of China. Beijing: China Medical Science Press; 2020.
- European Pharmacopoeia. 10th ed. European Directorate for the Quality of Medicines & HealthCare (EDQM); 2020.
- British Pharmacopoeia. 2021 ed. British Pharmacopoeia Commission; 2021.
- Japanese Pharmacopoeia. 18th ed. Tokyo: Ministry of Health LaW; 2021.
- Lu M, Jiancun Z, Zhigang C, et al. Investigation of insoluble particles in intravenous infusion drugs. Chin Pharm J. 2006;1:45–47.
- Walpot H, Franke RP, Burchard WG, et al. Particulate contamination of infusion solutions and drug additives in the framework of long-term intensive therapy. 2. An animal model. Anaesthesist. 1989;38(11):617–621.
- Stehbens WE, Florey HW. The behaviour of intravenously injected particles observed in chambers in rabbits’ ears. Q J Exp Physiol Cogn Med Sci. 1960;45(3):252–264. doi: 10.1113/expphysiol.1960.sp001470.
- Lehr HA, Brunner J, Rangoonwala R, et al. Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med. 2002;165(4):514–520. doi: 10.1164/ajrccm.165.4.2108033.
- Hongliang W. Analysis of the causes and control strategies of insoluble particles in chemical injection. Drug Eval Res. 2022;45(9):1909–1913.
- Bing W, Meiying Z. Research progress on preventing harm of insoluble particles in intravenous infusion. Shanghai Nurs. 2009;9(1):63–66.
- Kuramoto K, Shoji T, Nakagawa Y. Usefulness of the final filter of the IV infusion set in intravenous administration of drugs – contamination of injection preparations by insoluble microparticles and its causes. Yakugaku Zasshi. 2006;126(4):289–295. doi: 10.1248/yakushi.126.289.
- Zhen Z, Ying C, Wei W, et al. Effect of precision filter infusion set in operation room on prevention of infusion phlebitis. Jilin Med J. 2012;33(35):7797–7798.
- Penggao H, Changhuai L. Research progress on the pollution pathway and control method of insoluble particles in intravenous infusion. Med Inform. 2011;24(03):1236–1237.
- Yuhang W, Ying L, Yue C, et al. Systematic comparison between instant powder-liquid double-chamber bag and traditional packaging form. Chin J Hosp Pharm. 2013;33(21):1817–1819.